Skip to content
RUO · Research Use OnlyFor Long✓ Free to read

MOTS-c

Your own cells already make this one. The pitch is better metabolism, but it is unproven in people.

Updated 19 May 2026Read 3 minBacked by 60 studies
The quick version
What it is
A peptide your mitochondria (your cells' power plants) make on their own
Is it FDA-approved?
No. Sold 'for research only'
How strong is the proof?
Weak in people. Good mouse data, but zero finished human trials of this exact molecule
How you take it
A shot under the skin, often 5-10 mg a week
Typical result
Unknown in people. Mice handled blood sugar better
Biggest catch
No real human proof, and no long-term safety data

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

MOTS-c is a . The cool part is that your body already makes it. It comes from your mitochondria, the tiny power plants inside your cells.

It was discovered at a university (the Cohen lab at USC). It is one of the first peptides ever found that comes from mitochondrial DNA. In mice, it tells cells to burn sugar better and handle stress.

It is sold "for research only." Note: your levels of it naturally drop as you age. Whether injecting more does anything in a person is the open question.

What people use it for.

People use it for metabolism and longevity. The hope is better blood sugar, better insulin handling, and slower aging.

Athletes use it hoping for more endurance, based on a study where mice ran longer.

You will see it sold with the word "energy." That word is doing a lot of work. The science is about how cells handle fuel, not about the way a coffee makes you feel awake.

Does it actually work?

We do not know if it works in people. That is the honest answer.

There are zero finished human trials of the exact MOTS-c you would buy. A company did test a changed version called CB4211, but they shut that program down in 2022.

The good mouse data is real, and the biology is genuinely new and interesting. But mouse results often do not carry over to people. The "energy" most users report is probably the feeling of spending $110 a month on a longevity , not a measured change.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

MOTS-c is exercise in a vial, you get the benefits of a workout from a shot.

unproven

That idea comes from mice that ran longer on a treadmill. There are zero finished human trials of the exact molecule you would buy, so the workout-in-a-shot claim has no human proof.

Your own cells make it, so injecting more is safe.

not quite

Your mitochondria do make a trace, and your levels drop as you age. But there is no long-term safety data on injecting extra. You would be one of the early testers.

It gives you real energy.

overblown

The science is about how cells handle fuel, not the awake feeling from coffee. In a healthy person, the 'energy' is hard to tell apart from the feeling of spending $110 a month on a longevity .

It fixes blood sugar and insulin.

unproven

Mice handled sugar better, but the one company that tested a tweaked human version, CB4211, shut the program down in 2022. No human result has confirmed it yet.

How you take it.

People take it as a shot under the skin. The common amount is about 5 to 10 mg a week, sometimes split into a few shots.

There is no tested, official dose, because there is no finished human trial of this molecule. The numbers people use come from the community, not a label.

If you try it, the smart move is to set a time limit, which we cover in our take.

What to watch out for.

There is not a long list of known side effects, but that is mostly because it has barely been studied in people. "We do not know" is not the same as "it is safe."

The serious stuff

There is no long-term safety data at all. You are an early tester.

If you have a known mitochondrial disorder, do not self-treat. That needs a specialist.

If you try it, get blood tests before and after so you can judge by real numbers, not by how you feel. Talk to a real doctor first. We are not your doctor.

Where people get it.

Here are the ways people get it, from safest to riskiest.

  • Brand. None. No approved version exists.
  • . Only a handful of longevity clinics make it, for about $150–$400 a month. The big-name clinics usually do not carry it.
  • Research-only (). The main supply, about $110–$300 a month. Sold "for research only."
  • . Overseas raw, much cheaper at about $15–$30 a month. Same molecule, but no lab report and no oversight.

One quality note: MOTS-c is a longer and hard to make well. Vials under 95 percent pure are common. Ask for a showing purity by so you are not paying for junk.

Our honest take.

One of the first peptides anyone found hiding inside mitochondrial DNA, and your own cells already make it. That part is genuinely new. New and proven are not the same thing, though. There are zero finished human trials of the exact molecule you would buy, and the one company that tested a tweaked version shut the program down in 2022.

So buying it means running the study on yourself. If you are healthy, the "energy" people report is hard to tell apart from the feeling of spending $110 a month on a longevity .

If you have real pre-diabetes or insulin trouble and want to test it anyway, set a hard 12-week limit, pull full before-and-after labs, and let the numbers call it, not the vibe. That is the honest way to run an experiment of one.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

  1. 01Gao Y, et al. MOTS-c Functionally Prevents Metabolic Disorders. Metabolites. 2023;13(1). PMID: 36677050.
  2. 02Kumagai H, et al. MOTS-c reduces myostatin and muscle atrophy signaling. American journal of physiology. Endocrinology and metabolism. 2021;320(4):E680-E690. PMID: 33554779.
  3. 03Zheng Y, et al. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in endocrinology. 2023;14:1120533. PMID: 36761202.
  4. 04Benayoun BA, et al. MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus. BioEssays : news and reviews in molecular, cellular and developmental biology. 2019;41(9):e1900046. PMID: 31378979.
  5. 05Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell metabolism. 2015;21(3):443-54. PMID: 25738459.
  6. 06Yin Y, et al. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024;11(43):e2405620. PMID: 39321430.
  7. 07Zhang Z, et al. MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria. Mitochondrion. 2023;71:76-82. PMID: 37307934.
  8. 08Yin Y, et al. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacological research. 2022;175:105987. PMID: 34798268.
  9. 09Yi X, et al. Role of MOTS-c in the regulation of bone metabolism. Frontiers in physiology. 2023;14:1149120. PMID: 37200834.
  10. 10Lin C, et al. Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection. Gut. 2024;73(2):338-349. PMID: 37788894.
  11. 11Mohtashami Z, et al. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. International journal of molecular sciences. 2022;23(19). PMID: 36233287.
  12. 12Kumagai H, et al. MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience. 2024;27(11):111212. PMID: 39559755.
  13. 13Wan W, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of translational medicine. 2023;21(1):36. PMID: 36670507.
  14. 14Fu Y, et al. MOTS-c regulates the ROS/TXNIP/NLRP3 pathway to alleviate diabetic cardiomyopathy. Biochemical and biophysical research communications. 2024;741:151072. PMID: 39616938.
  15. 15Li X, et al. MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes. Redox biology. 2025;84:103681. PMID: 40403491.
  16. 16Kong BS, et al. Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases. Diabetes & metabolism journal. 2023;47(3):315-324. PMID: 36824008.
  17. 17Kim KH, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell metabolism. 2018;28(3):516-524.e7. PMID: 29983246.
  18. 18Fang T, et al. MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications and potential treatment. Life sciences. 2025;382:124009. PMID: 41083123.
  19. 19Yerra VG, et al. MOTS-c: Magical Molecule for Diabetic Cardiomyopathy?. Cardiovascular drugs and therapy. 2025;39(3):473-476. PMID: 40172798.
  20. 20García-Benlloch S, et al. MOTS-c promotes muscle differentiation in vitro. Peptides. 2022;155:170840. PMID: 35842023.
  21. 21Zhang Y, et al. The Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism. Antioxidants (Basel, Switzerland). 2024;13(5). PMID: 38790718.
  22. 22Kumagai H, et al. Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration. American journal of physiology. Endocrinology and metabolism. 2024;326(3):E207-E214. PMID: 38170165.
  23. 23Jia H, et al. Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane. Theranostics. 2024;14(13):5001-5021. PMID: 39267782.
  24. 24Shen Z, et al. MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. American journal of respiratory cell and molecular biology. 2025;73(3):353-368. PMID: 40035775.
  25. 25Lee C, et al. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free radical biology & medicine. 2016;100:182-187. PMID: 27216708.
  26. 26Wang M, et al. MOTS-c repairs myocardial damage by inhibiting the CCN1/ERK1/2/EGR1 pathway in diabetic rats. Frontiers in nutrition. 2023;9:1060684. PMID: 36687680.
  27. 27Bień J, et al. MOTS-c regulates pancreatic alpha and beta cell functions in vitro. Histochemistry and cell biology. 2024;161(6):449-460. PMID: 38430258.
  28. 28Zhang W, et al. MOTS-c attenuates airway barrier dysfunction in allergic asthma by inhibiting epithelial apoptosis via Nrf2 pathway. International immunopharmacology. 2025;161:115014. PMID: 40472776.
  29. 29Chen F, et al. MOTS-c mimics exercise to combat diabetic liver fibrosis by targeting Keap1-Nrf2-Smad2/3. Scientific reports. 2025;15(1):18460. PMID: 40425777.
  30. 30Yoon TK, et al. Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c). Diabetes & metabolism journal. 2022;46(3):402-413. PMID: 35656563.
  31. 31Kong BS, et al. Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & molecular medicine. 2025;57(8):1861-1877. PMID: 40855115.
  32. 32Li K, et al. MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free radical biology & medicine. 2025;241:717-731. PMID: 41043625.
  33. 33Lu H, et al. The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. Cell reports. 2024;43(1):113587. PMID: 38206815.
  34. 34Lu H, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. Journal of molecular medicine (Berlin, Germany). 2019;97(4):473-485. PMID: 30725119.
  35. 35Lin Y, et al. MOTS-c-modified functional self-assembly peptide hydrogels enhance the activity of nucleus pulposus-derived mesenchymal stem cells of intervertebral disc degeneration. Materials today. Bio. 2025;32:101872. PMID: 40510834.
  36. 36Wang DD, et al. MOTS-c mimics remote ischemic preconditioning in protecting against lung ischemia-reperfusion injury by alleviating endothelial barrier dysfunction. Free radical biology & medicine. 2025;229:127-138. PMID: 39827923.
  37. 37Kim SJ, et al. MOTS-c: an equal opportunity insulin sensitizer. Journal of molecular medicine (Berlin, Germany). 2019;97(4):487-490. PMID: 30788534.
  38. 38Li S, et al. MOTS-c and Exercise Restore Cardiac Function by Activating of NRG1-ErbB Signaling in Diabetic Rats. Frontiers in endocrinology. 2022;13:812032. PMID: 35370955.
  39. 39Bahar MR, et al. Effects of intracerebroventricular MOTS-c infusion on thyroid hormones and uncoupling proteins. Biologia futura. 2023;74(1-2):159-170. PMID: 37067760.
  40. 40Zicarelli M, et al. MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study. Medicina (Kaunas, Lithuania). 2025;61(2). PMID: 40005438.
  41. 41Lu P, et al. The mitochondrial-derived peptide MOTS-c suppresses ferroptosis and alleviates acute lung injury induced by myocardial ischemia reperfusion via PPARγ signaling pathway. European journal of pharmacology. 2023;953:175835. PMID: 37290680.
  42. 42Bhullar KS, et al. Mitofusion is required for MOTS-c induced GLUT4 translocation. Scientific reports. 2021;11(1):14291. PMID: 34253808.
  43. 43Yuan J, et al. MOTS-c and aerobic exercise induce cardiac physiological adaptation via NRG1/ErbB4/CEBPβ modification in rats. Life sciences. 2023;315:121330. PMID: 36584915.
  44. 44Tok A, et al. Serum MOTS-c levels remain unchanged in patients with preeclampsia. Ginekologia polska. 2023;94(8):633-637. PMID: 39469962.
  45. 45Tang M, et al. The role of MOTS-c-mediated antioxidant defense in aerobic exercise alleviating diabetic myocardial injury. Scientific reports. 2023;13(1):19781. PMID: 37957221.
  46. 46Li F, et al. Neuroprotective Mechanism of MOTS-c in TBI Mice: Insights from Integrated Transcriptomic and Metabolomic Analyses. Drug design, development and therapy. 2024;18:2971-2987. PMID: 39050800.
  47. 47Ozkaya DY, et al. MOTS-C levels ın ındividuals with and without obesity and ıts association with ınflammation, insulin resistance and endothelial dysfunction. Archives of endocrinology and metabolism. 2025;69(5):e250063. PMID: 41004666.
  48. 48Ozturk Öztürk DA, et al. Central MOTS-c infusion affects reproductive hormones in obese and non-obese rats. Neuroscience letters. 2024;826:137722. PMID: 38462167.
  49. 49Leciejewska N, et al. MOTS-c Impact on Muscle Cell Differentiation and Metabolism Across Fiber Types. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2025;59(1):34-46. PMID: 39876762.
  50. 50Wu J, et al. The protective effect of the mitochondrial-derived peptide MOTS-c on LPS-induced septic cardiomyopathy. Acta biochimica et biophysica Sinica. 2023;55(2):285-294. PMID: 36786072.
  51. 51Kong BS, et al. Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Cell reports. 2021;36(4):109447. PMID: 34320351.
  52. 52Chen D, et al. MOTS‑c protects against placental injury via Nrf2 activation in hypoxia‑induced intrauterine growth restriction mice. International journal of molecular medicine. 2026;57(1). PMID: 41268602.
  53. 53Cakmak A, et al. MOTS-c as a Potential Diagnostic-prognostic Biomarker for Myocardial Infarction. Cardiovascular & hematological agents in medicinal chemistry. 2025;23(3):209-222. PMID: 40353474.
  54. 54Cuyàs E, et al. Circulating levels of MOTS-c in patients with breast cancer treated with metformin. Aging. 2022;15(4):892-897. PMID: 36490309.
  55. 55Luo YH, et al. Serum MOTS-C Levels are Decreased in Obese Children and Associated with Vascular Endothelial Function. Diabetes, metabolic syndrome and obesity : targets and therapy. 2023;16:1013-1020. PMID: 37077579.
  56. 56Kamiński K, et al. Expression Patterns of MOTS-c in Adrenal Tumors: Results from a Preliminary Study. International journal of molecular sciences. 2024;25(16). PMID: 39201408.
  57. 57Yang L, et al. MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis. Acta biochimica et biophysica Sinica. 2024;56(9):1323-1339. PMID: 38716540.
  58. 58Edwards BA, et al. Mitochondria-derived peptide MOTS-c and its role in OSA pathogenesis: a potential therapeutic target?. Sleep and biological rhythms. 2025;23(3):261-262. PMID: 40538382.
  59. 59Wu N, et al. MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model. Cardiovascular drugs and therapy. 2025;39(3):491-498. PMID: 38141139.
  60. 60Pham T, et al. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Frontiers in physiology. 2025;16:1602271. PMID: 40661667.

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.